We love to hear from our listeners. Send us a message. On this week&#x27;s episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a &quot;bioAI&quot; company using synthetic DNA switches and cancer-binding lipid nanoparticles to transform cancer cells into immune therapy-producing factories in vivo. Cyriac also discusses China’s newest five-year plan for biotech (2026 to 2030), why U.S. funding cycles are pushing innovation offshore, and how a U.S. sovereign wealth fund could support preclinical and early-stage drug development leadership at home. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding

Business Of Biotech

[SPEAKER_00] Welcome back to the Business of Biotech. I'm your host, Ben Comer, Chief Editor at Life Science Leader. And today I'm speaking with Cyriac Roeding, a serial entrepreneur and investor in the fields of technology, AI, and science broadly. He built CBS's mobile unit. And as entrepreneur in residence at Kleiner Perkins, he co-founded Shopkick, a shopping app sold to a Korean telecoms company for $250 million.

[SPEAKER_00] He's now CEO and co-founder at Early, a tech bio company that uses genetic constructs to turn cancer cells against themselves, which I'll get him to explain. Cyriac is a keen observer of technological trends and startups and predicted in 2016 that China would become Silicon Valley's biggest rival. He's an investor in a bunch of companies, including OpenAI and venture capital funds through his family office, Roeding Ventures.

[SPEAKER_00] And I'm excited to have Cyriac on the show today for two primary purposes, to talk about early story in cancer and what it takes to make a startup succeed. And second, what China's five-year plan in biotech means for biotech companies everywhere else. Cyriac, thank you so much for being here.

[SPEAKER_01] Pleasure to be here. I'm looking forward to the conversation.

[SPEAKER_00] Me too. And I want to start off with a couple of background questions, as we do here on the business of biotech. I read in your bio, Cyriac, that you sold your first computer program in Germany when you were 15 years old. What was that program? And is that, you know, when you were first bit by the entrepreneurial bug or did that come later?

Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.